Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease

Trial Profile

ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms ACCENT-I
  • Sponsors Centocor
  • Most Recent Events

    • 08 Jun 2018 New trial record
    • 05 Jun 2018 Results of a pooled analysis of ACCENT-I, SONIC, ACT-1, and ACT-2 (n=1205) assessing the association between obesity and response to infliximab, published in the American Journal of Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top